{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:02:00Z","timestamp":1792699320478,"version":"4.5.0"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.exphem.2025.105339","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T23:54:43Z","timestamp":1766447683000},"page":"105339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Polycomb repressive complexes as therapeutic targets in hematologic malignancies"],"prefix":"10.1016","volume":"155","author":[{"given":"Makoto","family":"Yamagishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Iwama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8409-0407","authenticated-orcid":false,"given":"Issay","family":"Kitabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2025.105339_bib0001","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cell.2017.08.002","article-title":"Genome regulation by polycomb and trithorax: 70 years and counting","volume":"171","author":"Schuettengruber","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2025.105339_bib0002","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2017-02-739490","article-title":"Polycomb repressive complexes in hematological malignancies","volume":"130","author":"Iwama","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0003","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.exphem.2018.10.008","article-title":"Emerging role of noncanonical polycomb repressive complexes in normal and malignant hematopoiesis","volume":"68","author":"Isshiki","year":"2018","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2025.105339_bib0004","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/sj.leu.2404623","article-title":"Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia","volume":"21","author":"Chowdhury","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.105339_bib0005","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.bcmd.2014.07.002","article-title":"BMI1 gene expression in myeloid leukemias and its impact on prognosis","volume":"53","author":"Saudy","year":"2014","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.exphem.2025.105339_bib0006","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood-2005-06-2393","article-title":"Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis","volume":"107","author":"Mihara","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0007","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00277-010-1128-5","article-title":"Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring","volume":"90","author":"Xu","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2025.105339_bib0008","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0002-9440(10)64583-X","article-title":"Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin\u2019s disease","volume":"157","author":"Raaphorst","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.exphem.2025.105339_bib0009","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood.V97.12.3896","article-title":"Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma","volume":"97","author":"van Kemenade","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1136\/jcp.2006.038752","article-title":"Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL","volume":"60","author":"van Galen","year":"2007","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.exphem.2025.105339_bib0011","first-page":"2409","article-title":"BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas","volume":"61","author":"Bea","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2025.105339_bib0012","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood-2015-08-662593","article-title":"Polycomb-dependent epigenetic landscape in adult T-cell leukemia","volume":"127","author":"Fujikawa","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0013","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/cas.13326","article-title":"Novel orally bioavailable EZH1\/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor","volume":"108","author":"Honma","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1016\/j.exphem.2025.105339_bib0014","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41580-021-00398-y","article-title":"The molecular principles of gene regulation by Polycomb repressive complexes","volume":"22","author":"Blackledge","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.exphem.2025.105339_bib0015","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41576-022-00499-0","article-title":"Context-specific polycomb mechanisms in development","volume":"23","author":"Kim","year":"2022","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.exphem.2025.105339_bib0016","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1016\/j.molcel.2024.07.030","article-title":"Navigating the complexity of Polycomb repression: enzymatic cores and regulatory modules","volume":"84","author":"Tamburri","year":"2024","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2025.105339_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2019.04.002","article-title":"Functional landscape of PCGF proteins reveals both RING1A\/B-dependent-and RING1A\/B-independent-specific activities","volume":"74","author":"Scelfo","year":"2019","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2025.105339_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2019.03.024","article-title":"Synergy between variant PRC1 complexes defines polycomb-mediated gene repression","volume":"74","author":"Fursova","year":"2019","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2025.105339_bib0019","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1042\/BST20230336","article-title":"Polycomb-mediated histone modifications and gene regulation","volume":"52","author":"Ito","year":"2024","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.exphem.2025.105339_bib0020","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.cell.2014.05.004","article-title":"Variant PRC1 complex-dependent H2A ubiquitylation drives PRC2 recruitment and polycomb domain formation","volume":"157","author":"Blackledge","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2025.105339_bib0021","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.molcel.2019.07.031","article-title":"Non-core subunits of the PRC2 complex are collectively required for its target-site specificity","volume":"76","author":"Hojfeldt","year":"2019","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2025.105339_bib0022","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.molcel.2019.08.012","article-title":"PRC2.1 and PRC2.2 synergize to coordinate H3K27 trimethylation","volume":"76","author":"Healy","year":"2019","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2025.105339_bib0023","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.celrep.2012.11.026","article-title":"RYBP and Cbx7 define specific biological functions of polycomb complexes in mouse embryonic stem cells","volume":"3","author":"Morey","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2025.105339_bib0024","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.83004","article-title":"Polycomb repressive complex 1.1 coordinates homeostatic and emergency myelopoiesis","volume":"12","author":"Nakajima-Takagi","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.exphem.2025.105339_bib0025","doi-asserted-by":"crossref","first-page":"18439","DOI":"10.1073\/pnas.0707292104","article-title":"Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases","volume":"104","author":"Hong","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2025.105339_bib0026","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10292","article-title":"BAP1\/ASXL1 recruitment and activation for H2A deubiquitination","volume":"7","author":"Sahtoe","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2025.105339_bib0027","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood.2022015668","article-title":"Noncanonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias","volume":"140","author":"Poplineau","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0028","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41556-022-00850-x","article-title":"EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis","volume":"24","author":"Wang","year":"2022","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.exphem.2025.105339_bib0029","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nature01587","article-title":"Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells","volume":"423","author":"Park","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2025.105339_bib0030","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1084\/jem.20052477","article-title":"Differential impact of Ink4a and Arf on hematopoietic stem cells and their bone marrow microenvironment in Bmi1-deficient mice","volume":"203","author":"Oguro","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2025.105339_bib0031","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2004.11.004","article-title":"Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1","volume":"21","author":"Iwama","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2025.105339_bib0032","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.stem.2010.01.005","article-title":"Poised lineage specification in multipotential hematopoietic stem and progenitor cells by the polycomb protein Bmi1","volume":"6","author":"Oguro","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2025.105339_bib0033","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/leu.2016.2","article-title":"BCOR regulates myeloid cell proliferation and differentiation","volume":"30","author":"Cao","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.105339_bib0034","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1182\/blood-2018-01-827964","article-title":"Bcor insufficiency promotes initiation and progression of myelodysplastic syndrome","volume":"132","author":"Tara","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0035","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood-2015-03-634428","article-title":"Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner","volume":"126","author":"Mochizuki-Kashio","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0036","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.stem.2012.08.001","article-title":"Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest","volume":"11","author":"Hidalgo","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2025.105339_bib0037","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.stem.2013.10.001","article-title":"Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner","volume":"14","author":"Xie","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2025.105339_bib0038","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2014-12-615898","article-title":"Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis","volume":"126","author":"Lee","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0039","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1371\/journal.pbio.0060093","article-title":"Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activity","volume":"6","author":"Majewski","year":"2008","journal-title":"PLoS Biol"},{"key":"10.1016\/j.exphem.2025.105339_bib0040","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood-2009-12-260760","article-title":"Opposing roles of polycomb repressive complexes in hematopoietic stem and progenitor cells","volume":"116","author":"Majewski","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0041","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41591-021-01411-9","article-title":"Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis","volume":"27","author":"Saiki","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2025.105339_bib0042","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood.2021011320","article-title":"Clinical relevance of clonal hematopoiesis in persons aged \u226580 years","volume":"138","author":"Rossi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0043","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/s41591-022-01883-3","article-title":"Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects","volume":"28","author":"Robertson","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2025.105339_bib0044","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1038\/s41591-023-02636-6","article-title":"Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease","volume":"29","author":"Spencer Chapman","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2025.105339_bib0045","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0092-8674(91)90382-9","article-title":"Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging","volume":"65","author":"van Lohuizen","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2025.105339_bib0046","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood-2006-12-065599","article-title":"The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia","volume":"110","author":"Mohty","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0047","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/leu.2010.325","article-title":"Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein","volume":"25","author":"Yong","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.105339_bib0048","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/gcc.22088","article-title":"BMI1, the polycomb-group gene, is recurrently targeted by genomic rearrangements in progressive B-cell leukemia\/lymphoma","volume":"52","author":"Rouhigharabaei","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.exphem.2025.105339_bib0049","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/leu.2011.85","article-title":"Bmi1 is essential for leukemic reprogramming of myeloid progenitor cells","volume":"25","author":"Yuan","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.105339_bib0050","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1097-2765(03)00277-6","article-title":"Bmi-1 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1","volume":"12","author":"Smith","year":"2003","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2025.105339_bib0051","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nature01572","article-title":"Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells","volume":"423","author":"Lessard","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2025.105339_bib0052","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1182\/blood-2010-02-270660","article-title":"BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells","volume":"116","author":"Rizo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0053","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2011-06-359232","article-title":"Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells","volume":"119","author":"Sengupta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0054","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.celrep.2015.12.034","article-title":"Non-canonical PRC1.1 Targets active genes independent of H3K27me3 and is essential for leukemogenesis","volume":"14","author":"van den Boom","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2025.105339_bib0055","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1600972","article-title":"Maintenance of leukemic cell identity by the activity of the Polycomb complex PRC1 in mice","volume":"2","author":"Rossi","year":"2016","journal-title":"Sci Adv"},{"key":"10.1016\/j.exphem.2025.105339_bib0056","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2017-05-787226","article-title":"Ring1A and Ring1B inhibit expression of Glis2 to maintain murine MOZ-TIF2 AML stem cells","volume":"131","author":"Shima","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0057","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1073\/pnas.0608721104","article-title":"Role of the chromobox protein CBX7 in lymphomagenesis","volume":"104","author":"Scott","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2025.105339_bib0058","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccr.2011.09.008","article-title":"CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis","volume":"20","author":"Tan","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2025.105339_bib0059","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1158\/1055-9965.EPI-10-0638","article-title":"Variations in chromosomes 9 and 6p21.3 with risk of non-Hodgkin lymphoma","volume":"20","author":"Wang","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.exphem.2025.105339_bib0060","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1182\/blood-2011-07-365320","article-title":"Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype","volume":"118","author":"Grossmann","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0061","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0062","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1182\/blood-2012-11-469619","article-title":"BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders","volume":"122","author":"Damm","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0063","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/gcc.22348","article-title":"Frequent BCOR aberrations in extranodal NK\/T-Cell lymphoma, nasal type","volume":"55","author":"Dobashi","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.exphem.2025.105339_bib0064","doi-asserted-by":"crossref","first-page":"17764","DOI":"10.18632\/oncotarget.3776","article-title":"Genetic alterations of JAK\/STAT cascade and histone modification in extranodal NK\/T-cell lymphoma nasal type","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2025.105339_bib0065","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2025.105339_bib0066","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/gcc.22313","article-title":"Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker","volume":"55","author":"Stengel","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.exphem.2025.105339_bib0067","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature25795","article-title":"Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours","volume":"555","author":"Ma","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2025.105339_bib0068","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1182\/blood-2011-05-356204","article-title":"Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia","volume":"118","author":"Li","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0069","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3324\/haematol.2010.028605","article-title":"Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia\/lymphoma as a target for epigenetic therapy","volume":"96","author":"Sasaki","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2025.105339_bib0070","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1046\/j.1365-2141.2001.02641.x","article-title":"The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma","volume":"112","author":"Visser","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2025.105339_bib0071","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2025.105339_bib0072","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.1116418109","article-title":"Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)","volume":"109","author":"McCabe","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2025.105339_bib0073","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"Beguelin","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2025.105339_bib0074","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-017-01029-x","article-title":"EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop","volume":"8","author":"Beguelin","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2025.105339_bib0075","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic Target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2025.105339_bib0076","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.2651","article-title":"Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia","volume":"18","author":"Ntziachristos","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2025.105339_bib0077","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2025.105339_bib0078","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2025.105339_bib0079","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes","volume":"42","author":"Nikoloski","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2025.105339_bib0080","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2011-07-367243","article-title":"Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic\/myeloproliferative neoplasms","volume":"119","author":"Score","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0081","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/onc.2014.196","article-title":"\u22127\/7q\u2212 syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity","volume":"34","author":"Honda","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2025.105339_bib0082","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood-2011-11-394932","article-title":"Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia","volume":"120","author":"Tanaka","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0083","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1084\/jem.20131144","article-title":"Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders","volume":"210","author":"Muto","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2025.105339_bib0084","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nchembio.1331","article-title":"Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer","volume":"9","author":"Kim","year":"2013","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.exphem.2025.105339_bib0085","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1073\/pnas.1202258109","article-title":"Polycomb repressive complex 2 is required for MLL-AF9 leukemia","volume":"109","author":"Neff","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2025.105339_bib0086","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/onc.2012.110","article-title":"The polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia","volume":"32","author":"Shi","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2025.105339_bib0087","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/leu.2017.300","article-title":"Dual inhibition of EZH1\/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia","volume":"32","author":"Fujita","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.105339_bib0088","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological aspects and world distribution of HTLV-1 Infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Front Microbiol"},{"key":"10.1016\/j.exphem.2025.105339_bib0089","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1200\/JCO.18.00501","article-title":"Revised adult T-cell Leukemia-lymphoma international consensus meeting report","volume":"37","author":"Cook","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2025.105339_bib0090","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2025.105339_bib0091","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1038\/s41467-021-25101-9","article-title":"Chronological genome and single-cell transcriptome integration characterizes the evolutionary process of adult T cell leukemia-lymphoma","volume":"12","author":"Yamagishi","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2025.105339_bib0092","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ccr.2011.12.015","article-title":"Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kappaB pathway in adult T cell leukemia and other cancers","volume":"21","author":"Yamagishi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2025.105339_bib0093","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.exphem.2025.105339_bib0094","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/acsmedchemlett.5b00037","article-title":"EPZ011989, A Potent, Orally-available EZH2 inhibitor with robust in vivo activity","volume":"6","author":"Campbell","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.exphem.2025.105339_bib0095","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1158\/1078-0432.CCR-18-4121","article-title":"Phase I study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors","volume":"25","author":"Yap","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2025.105339_bib0096","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1080\/10428194.2018.1430795","article-title":"Enhancer of zeste homolog 2 (EZH2) inhibitors","volume":"59","author":"Gulati","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2025.105339_bib0097","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2025.105339_bib0098","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.molcel.2008.11.004","article-title":"Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms","volume":"32","author":"Margueron","year":"2008","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2025.105339_bib0099","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molcel.2008.10.016","article-title":"EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency","volume":"32","author":"Shen","year":"2008","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2025.105339_bib0100","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","article-title":"Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas","volume":"29","author":"Yamagishi","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2025.105339_bib0101","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2022016862","article-title":"An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma","volume":"141","author":"Izutsu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105339_bib0102","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S1470-2045(24)00503-5","article-title":"Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study","volume":"25","author":"Zinzani","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2025.105339_bib0103","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-024-07103-x","article-title":"Mechanisms of action and resistance in histone methylation-targeted therapy","volume":"627","author":"Yamagishi","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2025.105339_bib0104","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1158\/1078-0432.CCR-23-3383","article-title":"A phase I\/II study of valemetostat (DS-3201b), an EZH1\/2 inhibitor, in combination with irinotecan in patients with recurrent small-cell lung Cancer","volume":"30","author":"Choudhury","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2025.105339_bib0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.omto.2022.09.006","article-title":"Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors","volume":"27","author":"Shinohara","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.exphem.2025.105339_bib0106","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ccell.2025.01.013","article-title":"EZH1\/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models","volume":"43","author":"Porazzi","year":"2025","journal-title":"Cancer Cell"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X25006204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X25006204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T11:57:57Z","timestamp":1771415877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X25006204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":106,"alternative-id":["S0301472X25006204"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2025.105339","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polycomb repressive complexes as therapeutic targets in hematologic malignancies","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2025.105339","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Experimental Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105339"}}